CTL partners with Daiichi Sankyo on Heartcel

10 May 2016

A private, UK-based cell therapy company has signed a partnership agreement giving Japanese drugmaker Daiichi Sankyo (TYO: 4568) the rights to develop and market its innovative cardiac stem-cell based regeneration medicine, Heartcel.

Under the terms of the deal, Cell Therapy Ltd (CTL), based in Cardiff, South Wales, will receive a £12.5 million upfront licensing fee and additional milestone payments and royalties.

Daiichi Sankyo will take responsibility for development, regulatory approval and marketing of Heartcel in Japan, while CTL will retain full rights in the rest of the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK